Encompass Wealth Advisors LLC Purchases Shares of 818 Novartis AG (NYSE:NVS)

Encompass Wealth Advisors LLC purchased a new stake in shares of Novartis AG (NYSE:NVS) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 818 shares of the company’s stock, valued at approximately $77,000.

A number of other institutional investors have also made changes to their positions in NVS. Argent Advisors Inc. raised its stake in Novartis by 3.3% in the 4th quarter. Argent Advisors Inc. now owns 3,719 shares of the company’s stock valued at $351,000 after acquiring an additional 118 shares during the period. STA Wealth Management LLC increased its position in shares of Novartis by 2.2% during the fourth quarter. STA Wealth Management LLC now owns 5,666 shares of the company’s stock valued at $535,000 after buying an additional 120 shares during the period. 9258 Wealth Management LLC increased its position in shares of Novartis by 3.5% during the fourth quarter. 9258 Wealth Management LLC now owns 3,593 shares of the company’s stock valued at $339,000 after buying an additional 120 shares during the period. Mid Atlantic Financial Management Inc. ADV increased its position in shares of Novartis by 2.8% during the fourth quarter. Mid Atlantic Financial Management Inc. ADV now owns 4,647 shares of the company’s stock valued at $439,000 after buying an additional 125 shares during the period. Finally, Parkside Financial Bank & Trust increased its position in shares of Novartis by 3.6% during the fourth quarter. Parkside Financial Bank & Trust now owns 3,719 shares of the company’s stock valued at $352,000 after buying an additional 130 shares during the period. 9.86% of the stock is owned by institutional investors and hedge funds.

Shares of Novartis stock opened at $86.30 on Thursday. The company has a quick ratio of 0.69, a current ratio of 0.91 and a debt-to-equity ratio of 0.49. The company has a market cap of $197.51 billion, a PE ratio of 27.93, a P/E/G ratio of 1.76 and a beta of 0.59. The business has a 50 day moving average of $86.31 and a 200 day moving average of $88.58. Novartis AG has a 52 week low of $77.04 and a 52 week high of $98.52.

Novartis (NYSE:NVS) last posted its quarterly earnings data on Monday, January 25th. The company reported $1.34 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.37 by ($0.03). The firm had revenue of $12.77 billion during the quarter, compared to the consensus estimate of $12.86 billion. Novartis had a return on equity of 24.39% and a net margin of 14.71%. Novartis’s revenue for the quarter was up 3.0% compared to the same quarter last year. During the same quarter last year, the company posted $1.32 EPS. On average, research analysts anticipate that Novartis AG will post 5.8 earnings per share for the current year.

The company also recently disclosed an annual dividend, which was paid on Monday, March 15th. Shareholders of record on Friday, March 5th were issued a $3.3784 dividend. This is an increase from Novartis’s previous annual dividend of $3.04. The ex-dividend date was Thursday, March 4th. This represents a yield of 2.2%. Novartis’s dividend payout ratio is 39.69%.

Several research analysts have recently commented on NVS shares. Sanford C. Bernstein started coverage on Novartis in a report on Monday, March 22nd. They set a “market perform” rating for the company. Morgan Stanley reissued an “overweight” rating on shares of Novartis in a report on Tuesday, February 2nd. Cowen lowered Novartis from an “outperform” rating to a “market perform” rating and cut their target price for the stock from $110.00 to $105.00 in a research note on Monday, February 1st. Deutsche Bank Aktiengesellschaft initiated coverage on Novartis in a research note on Friday, January 15th. They set a “buy” rating for the company. Finally, Barclays reissued an “underweight” rating on shares of Novartis in a research note on Friday, January 22nd. Two equities research analysts have rated the stock with a sell rating, four have issued a hold rating and six have assigned a buy rating to the company. Novartis has an average rating of “Hold” and a consensus price target of $108.50.

Novartis Company Profile

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products.

Read More: Marijuana Stocks

Institutional Ownership by Quarter for Novartis (NYSE:NVS)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.